



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	application filed within 10/807 766
				Filing Date	3/23/2004
				First Named Inventor	Dunn, James Patrick et al.
				Group Art Unit	to be assigned 1626
				Examiner Name	to be assigned Jason Nolan
Sheet	1	of	1	Attorney Docket Number	R0170B-REG

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
JN	A1	3,274,185		Sigal, Jr., et al.	09-20-1966	
JN	A2	3,813,384		Vogelsang, et al.	05-28-1974	
JN	A3	4,826,990		Musser, et al.	05-02-1989	
JN	A4	4,942,236		Musser, et al.	07-17-1990	
JN	A5	5,103,014		Musser, et al.	04-07-1992	
JN	A6	6,248,769		Cavalla, et al.	06-19-2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₀
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
JN	B1	EP	0 273 309	B1	Merrell Dow Pharma. (US)	01-11-1995		
JN	B2	EP	0 273 310	B1	Merrell Dow Pharma. (US)	06-21-1995		
JN	B3	WO	97/40017	A2	Novo Nordisk (DK)	10-30-1997		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
JN	C1	ROSEN, Gerald M., et al., "2-Benzyl-1,3,4-oxadiazolin-5-one and Related Compounds," Notes, Dept. of Chemistry, Clarkson College of Technology, Potsdam, NY, Aug. 1971, pp. 659-662		
JN	C2	De CLERCQ, Erik, "New Developments in Anti-HIV Chemotherapy," <i>Current Medicinal Chemistry</i> , 2001, pp. 1543-1572, vol. 8, No. 13, Bentham Science Publishers Ltd.		
JN	C3	BUCKHEIT, Jr., Robert W., "Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection, <i>Expert Opinion</i> , Investigative Drugs, Ashley Publications, Ltd., 2001, pp. 1423-1442, vol. 10, no. 8		
JN	C4	Del ELMO, Esther, et al., "Anti-Trypanosoma Activity of Some Natural Stilbenoids and Synthetic Related Heterocyclic Compounds", <i>Bioorganic & Medicinal Chemistry Letters</i> , 2001, pp. 2755-2757, No. 11		
JN	C5	Del ELMO, Esther, et al., "Leishmanicidal Activity of Some Stilbenoids and Related Heterocyclic Compounds," <i>Bioorganic & Medicinal Chemistry Letters</i> , 2001, pp.2123-2126, No. 11		
Examiner Signature		/Jason Nolan/	Date Considered	09/28/2006



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/807,766
Filing Date	March 23, 2004
First Named Inventor	James Patrick Dunn
Art Unit	TBA 1626
Examiner Name	TBA Jason Nolan
Attorney Docket Number	R0170B-REG

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
JN	A1	US 5,436,252	07-25-1995	Sorenson, et al.	
JN	A8	US- 5,331,002	07-19-1994	Miller, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
JN	B4	WO 98/04135-A1	02-05-1998	Bristol Myers Squibb		
JN	B5	WO 02/38553-A2	05-16-2002	Eli Lilly & Company		
JN	B6	WO 96/13264-A1	05-09-1996	Eli Lilly & Company		
JN	B7	EP 0 435 177-B1	07-03-1991	Dow Merrell Pharmaceuticals Inc.		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JN	C6	WILDER SMITH, A. E. "Preparation of some New 4-Substituted Derivatives of p-Amino-o-hydroxy-phenyl-1,3,4-oxadiazolone-5 and Study of their Mycobacteriostatic properties", <i>Arzneim. Forschung</i> 1967 67(17):768-772	
JN	C7	YÜKSEK, H. et al. "Synthesis and Antibacterial Activities of some 4,5-Dihydro- 1H-1,2,4-triazol-5-ones", <i>Arzneim. Forschung</i> 1997 47(4):405-409.	

Examiner
Signature

/Jason Nolan/

Date
Considered

09/28/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Doc. #125434



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Replacement form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/807,766
Filing Date	March 23, 2004
First Named Inventor	James Patrick Dunn
Art Unit	1014 1626
Examiner Name	TBA Jason Nolan
Attorney Docket Number	R0170B-REG

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ³
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			
JN	D1	WO 02/36576-A1	May 10, 2002	Kudos Pharmaceuticals Ltd and Maybridge PLC	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

Examiner Signature	/Jason Nolan/	Date Considered	09/28/2006
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Doc. #126348